Abstract
Introduction: Integrins are heterodimeric cell surface receptors, which enable adhesion, proliferation, and migration of cells by recognizing binding motifs in extracellular matrix (ECM) proteins. As transmembrane linkers between the cytoskeleton and the ECM, they are able to recruit a huge variety of proteins and to influence signaling pathways bidirectionally, thereby regulating gene expression and cell survival. Hence, integrins play a key role in various physiological as well as pathological processes, which has turned them into an attractive target for pharmaceutical research. Areas covered: In this review, the latest therapeutic developments of drug candidates and recently patented integrin ligands are summarized. Expert opinion: Integrins have been proven to be valuable therapeutic targets in the treatment of several inflammatory and autoimmune diseases, where leukocyte adhesion processes are regulated by them. Furthermore, they play an important role in pathological angiogenesis and tumor metastasis, being a promising target for cancer therapy. © 2013 Informa UK, Ltd.
Author supplied keywords
Cite
CITATION STYLE
Kapp, T. G., Rechenmacher, F., Sobahi, T. R., & Kessler, H. (2013, October). Integrin modulators: A patent review. Expert Opinion on Therapeutic Patents. https://doi.org/10.1517/13543776.2013.818133
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.